# BAY94-9027 PK Study Comparing to Another Long Acting Product

> **NCT03364998** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Damoctocog (Jivi, BAY94-9027)
- **DRUG:** Elocta

## Key facts

- **NCT ID:** NCT03364998
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-09-28
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364998, "BAY94-9027 PK Study Comparing to Another Long Acting Product". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03364998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*